Why the study?
Evidence needed to be compiled regarding the basic pharmacology and potential clinical aspects of levosimendan in cardiac surgery and other heart failure associated alterations to help guide future research.
Does levosimendan improve cardiac mechanical efficacy and reduce congestion compared to classical inotropes in patients with heart failure?
Does levosimendan improve cardiac mechanical efficacy and reduce congestion compared to classical inotropes in patients with heart failure?
Answers are grounded in this paper and cite their sources.
This review highlights the pharmacological profile of levosimendan and its potential clinical benefits over classical inotropes in heart failure and cardiac surgery.
ion and have been reported as emerging therapeutic alternative in HF cases. Levosimendan (LEVO) is an inodilator and with its unique pharmacology justifying its use in a wide range of cardiac alterations in HF particularly in undergoing cardiac surgery. It is also reported to be better than classical inotropes in maintaining cardiac mechanical efficacy and reducing congestion in acute HF with hypotension. This review paper was designed to compile various evidence about basic pharmacology and potential clinical aspects of LEVO in cardiac surgery and other HF associated alterations. This will benefit directly to the researcher in initiating research and to fill the gaps in the area of thrust.
No takes yet. Share an insight, caveat, or question.
Akhtar et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: